{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:38:10Z","timestamp":1791221890248,"version":"4.1.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.1001\/jamainternmed.2021.6759","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T16:04:03Z","timestamp":1637597043000},"page":"42","source":"Crossref","is-referenced-by-count":94,"title":["Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19"],"prefix":"10.1001","volume":"182","author":[{"given":"Brian M.","family":"Clemency","sequence":"first","affiliation":[{"name":"Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renoj","family":"Varughese","sequence":"additional","affiliation":[{"name":"Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaneicy","family":"Gonzalez-Rojas","sequence":"additional","affiliation":[{"name":"Verus Clinical Research Corporation, Coral Gables, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn G.","family":"Morse","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Phipatanakul","sequence":"additional","affiliation":[{"name":"Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Koster","sequence":"additional","affiliation":[{"name":"Instat Clinical Research, Chatham, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Blaiss","sequence":"additional","affiliation":[{"name":"Medical College of Georgia at Augusta University, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"ioi210069r1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19.","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"ioi210069r2","doi-asserted-by":"publisher","first-page":"20935","DOI":"10.1038\/s41598-020-78054-2","article-title":"A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19.","volume":"10","author":"Shuto","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"ioi210069r3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools.","volume":"35","author":"Fu","year":"2020","journal-title":"Virol Sin"},{"issue":"5","key":"ioi210069r4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19.","volume":"55","author":"Zhai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"ioi210069r5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1164\/rccm.202003-0821OC","article-title":"COVID-19-related genes in sputum cells in asthma: relationship to demographic features and corticosteroids.","volume":"202","author":"Peters","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"ioi210069r6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00130-2021","article-title":"Inhaled corticosteroids downregulate SARS-CoV-2\u2013related genes in COPD: results from a randomised controlled trial.","volume":"58","author":"Milne","year":"2021","journal-title":"Eur Respir J"},{"issue":"7","key":"ioi210069r7","doi-asserted-by":"publisher","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ioi210069r8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jaci.2020.05.029","article-title":"Molecular pharmacology of ciclesonide against SARS-CoV-2.","volume":"146","author":"Kimura","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"ioi210069r9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jiac.2020.04.007","article-title":"Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: report of three cases.","volume":"26","author":"Iwabuchi","year":"2020","journal-title":"J Infect Chemother"},{"issue":"10","key":"ioi210069r10","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1007\/s11606-020-06081-w","article-title":"Racial and ethnic disparities in population-level COVID-19 mortality.","volume":"35","author":"Gross","year":"2020","journal-title":"J Gen Intern Med"},{"key":"ioi210069r11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s43856-021-00006-2","article-title":"Analysis of sex-specific risk factors and clinical outcomes in COVID-19.","volume":"1","author":"Jun","year":"2021","journal-title":"Commun Med"},{"issue":"11","key":"ioi210069r12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241742","article-title":"Predictors of in-hospital COVID-19 mortality: a comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions.","volume":"15","author":"Mesas","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"ioi210069r13","doi-asserted-by":"publisher","first-page":"773","DOI":"10.7326\/M20-3742","article-title":"Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization.","volume":"173","author":"Tartof","year":"2020","journal-title":"Ann Intern Med"},{"issue":"5","key":"ioi210069r14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1017\/S002221512100116X","article-title":"Six-month smell and taste recovery rates in coronavirus disease 2019 patients: a prospective psychophysical study.","volume":"135","author":"Petrocelli","year":"2021","journal-title":"J Laryngol Otol"},{"issue":"7","key":"ioi210069r15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/pharmaceutics13071077","article-title":"Inhalation delivery for the treatment and prevention of COVID-19 infection.","volume":"13","author":"Eedara","year":"2021","journal-title":"Pharmaceutics"},{"key":"ioi210069r16","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100039","article-title":"PAK1-blockers: potential therapeutics against COVID-19.","volume":"6","author":"Maruta","year":"2020","journal-title":"Med Drug Discov"},{"issue":"1","key":"ioi210069r17","doi-asserted-by":"publisher","first-page":"e01648","DOI":"10.1128\/JVI.01648-20","article-title":"The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells.","volume":"95","author":"Matsuyama","year":"2020","journal-title":"J Virol"},{"issue":"21","key":"ioi210069r18","first-page":"1","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.","volume":"19","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"ioi210069r20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome.","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat Med"},{"key":"ioi210069r19","doi-asserted-by":"crossref","unstructured":"Yu? LM, Bafadhel? M, Dorward? J, . Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial.? medRxiv. Posted April 12, 2021. doi:10.1101\/2021.04.10.21254672","DOI":"10.1101\/2021.04.10.21254672"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2786012\/jamainternal_clemency_2021_oi_210069_1640813839.52604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T16:11:38Z","timestamp":1641312698000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2786012"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2021.6759","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}